Featured Buyer Profile

This weeks Featured Buyer seeks add-on acquisitions with the following criteria: Annual revenue greater than $2 million Annual earnings greater than $500,000 up to $9 million Preference for business services, software and value-add distribution Owner: seeking liquidity and/or exit from business, retiring without successor, desires a more focused role (ex. technical, sales, advisory role) If […]

Read more

The State of M&A: Partnering with Strategics

 Schedule A Consultation I am looking forward to moderating a panel of industry experts at the upcoming BIOMEDevice Boston show as part of the Master Class Start-Up Series sponsored by MassMEDIC. This Conference is tailored to providing the knowledge growing companies need to not only function, but be successful in the ever-changing landscape that is […]

Read more

Top 10 Issues To Consider To Create Value

As we work on M&A with both established middle-market medtech businesses and early-stage companies, we’re often asked about successful paths to exit for both types of organizations. For this month’s discussion, we’ll focus on the Top 10 Issues to address to create value to attract attention with a larger strategic industry player for a possible […]

Read more

Dave Sheppard Guest Speaker at Medical Manufacturing Asia 2022

MedWorld Advisors was proud to exhibit at Medical Manufacturing Asia 2022 in Singapore this past week. Held from August 31 to September 2, 2022, this show is a marketplace for suppliers of medical manufacturing with a focus on innovations from micro and nanotechnology like modules and components for medical technology, lab-on-a-chip technology, inspection equipment and […]

Read more

Featured Buyer Profile

This weeks Featured Buyer seeks add-on acquisitions with the following criteria: EBITDA $1-$5M Industry: Healthcare Services, Healthcare IT, Provider Based Platforms Hold period of 10+ years Founder owned If you’re interested in speaking with this potential acquirer (or know someone who may benefit from an introduction), please feel free to reach out to Dave Sheppard […]

Read more

Join MedWorld Advisors at…

Join us at BIOMEDevice Boston September 28-29th! We will be hosting a panel discussion September 29th with several industry professionals. Sponsored by our friends at MassMEDIC, this panel is one you won’t want to miss. Register today and stay tuned for more information about our panelists! October 6th 12PM-1PM ET, CEO Florence Joffroy-Black and Managing […]

Read more

How an Idea Reaches Strategic Buyers

Ever wondered how business opportunities move up the chain on the buyer side? A recent conversation with three MedTech M&A executives helped shed some light on what goes on behind the scenes when ideas are presented to large strategics.  At a panel hosted by Dave Sheppard of MedWorld Advisors, guests Eric Knudsen of ZOLL Medical, […]

Read more

Considering The Impacts of Industry Strategics

As many of us reading TMD either work for a major industry strategic or a company selling to one or competing with one, it’s easy to comprehend these goliaths have an impact on all of us. Here are the top 6 that we identified: Market leader:Most of these companies tend to be in the top […]

Read more

MedTech M&A Series: A Strategic Buyer’s Perspective

Listen to Co-Founder and Managing Director Dave Sheppard’s conversation with Charlie Attlan of Boston Scientific, Eric Knudsen of ZOLL Medical, and Tom Gales of Draeger. As part of our MedTech M&A Series, the panel for A Strategic Buyer’s Perspective discussed everything from how M&A strategy fits into their respective companies to deal origination and structure. Click […]

Read more

MedTech M&A Series: A Financial Buyer’s Perspective

Listen to Daniel Sheppard’s conversation with Eric Tansky, General Partner at Accelmed, Mike Magliochetti, PhD, Operating Partner at Riverside Partners, and Steve Sandbo, Principal at Vance Street Capital. In this installment, Dan covers everything from deal origination to transaction structure, as well as the MedTech/Healthcare M&A space as a whole from a private equity perspective. […]

Read more